News | January 25, 2026
Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
The company had achieved the highest "A" rating in Climate Change
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Granules India receives 1 observation from USFDA for Chantilly facility
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Subscribe To Our Newsletter & Stay Updated
